UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation

Frontiers in pharmacology, 2022-08, Vol.13, p.949264-949264

2022

Volltextzugriff (PDF)

Glycosylation of an N-Terminal Extension Prolongs the Half-Life and Increases the in Vivo Activity of Follicle Stimulating Hormone

The journal of clinical endocrinology and metabolism, 2003-07, Vol.88 (7), p.3227-3235

2003

Volltextzugriff (PDF)

Differentiation Between Binding Sites for Angiotensin II and Nonpeptide Antagonists on the Angiotensin II Type 1 Receptors

Proceedings of the National Academy of Sciences - PNAS, 1994-07, Vol.91 (15), p.7046-7050

1994

Volltextzugriff (PDF)

Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT1 Ligands: Susceptibility to Receptor Mutations

Molecular pharmacology, 1997-02, Vol.51 (2), p.301-311

1997

Volltextzugriff (PDF)

Identification of peptide binding residues in the extracellular domains of the AT1 receptor

The Journal of biological chemistry, 1994-12, Vol.269 (49), p.30953-30959

1994

Volltextzugriff (PDF)

Non-peptide Angiotensin Agonist

The Journal of biological chemistry, 1995-01, Vol.270 (4), p.1493-1496

1995

Volltextzugriff (PDF)

Molecular Mechanism of Action of Non-peptide Ligands for Peptide Receptors

Current pharmaceutical design, 1995-10, Vol.1 (3), p.325-342

1995

Volltextzugriff (PDF)

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor

The Journal of biological chemistry, 1995-01, Vol.270 (4), p.1493

1995

Volltextzugriff (PDF)

Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor

Molecular pharmacology, 1995-03, Vol.47 (3), p.425

1995

Volltextzugriff (PDF)

Mutations in transmembrane segment VIJ of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists

British journal of pharmacology, 1994-10, Vol.113 (2), p.331-333

1994

Volltextzugriff (PDF)

Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT 1 Ligands: Susceptibility to Receptor Mutations

Molecular pharmacology, 1997-02, Vol.51 (2), p.301-311

1997

Volltextzugriff (PDF)

Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits

Peritoneal dialysis international, 1992, Vol.12 (3), p.281-286

1992

Volltextzugriff (PDF)

Mutations in transmembrane segment VIJ of the AT 1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists

British journal of pharmacology, 1994-10, Vol.113 (2), p.331-333

1994

Volltextzugriff (PDF)

Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis (CAPD) Solutions. A Biocompatibility Study Involving Human Polymorphonuclear Granulocytes Rather than Laboratory Animals

Alternatives to laboratory animals, 1992-04, Vol.20 (2), p.275-279

1992

Volltextzugriff (PDF)

Molecular mechanism of activation and inhibition of 7TM peptide receptors

European journal of pharmaceutical sciences, 1994-09, Vol.2 (1), p.85-87

1994

Volltextzugriff (PDF)

Extracellular and intracellular small-molecule galectin-3 inhibitors

Scientific reports, 2019-02, Vol.9 (1), p.2186, Article 2186

2019

Volltextzugriff (PDF)

A Selective Galactose–Coumarin-Derived Galectin‑3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model

Journal of medicinal chemistry, 2016-09, Vol.59 (17), p.8141-8147

2016

Volltextzugriff (PDF)

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis

The European respiratory journal, 2021-05, Vol.57 (5), p.2002559

2021

Volltextzugriff (PDF)

Discovery and Optimization of the First Highly Effective and Orally Available Galectin‑3 Inhibitors for Treatment of Fibrotic Disease

Journal of medicinal chemistry, 2022-10, Vol.65 (19), p.12626-12638

2022

Volltextzugriff (PDF)

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

Cancer research (Chicago, Ill.), 2019-04, Vol.79 (7), p.1480-1492

2019

Volltextzugriff (PDF)

Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition

Chembiochem : a European journal of chemical biology, 2016-09, Vol.17 (18), p.1759-1770

2016

Volltextzugriff (PDF)

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

American journal of respiratory and critical care medicine, 2023-01, Vol.207 (2), p.138-149

2023

Volltextzugriff (PDF)

Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

Cancer chemotherapy and pharmacology, 2023-03, Vol.91 (3), p.267-280

2023

Volltextzugriff (PDF)

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)

Cancer chemotherapy and pharmacology, 2024-11, Vol.94 (5), p.707-720

2024

Volltextzugriff (PDF)

Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment

Clinical drug investigation, 2024-10

2024

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation

Glycosylation of an N-Terminal Extension Prolongs the Half-Life and Increases the in Vivo Activity of Follicle Stimulating Hormone

Differentiation Between Binding Sites for Angiotensin II and Nonpeptide Antagonists on the Angiotensin II Type 1 Receptors

Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT1 Ligands: Susceptibility to Receptor Mutations

Identification of peptide binding residues in the extracellular domains of the AT1 receptor

Non-peptide Angiotensin Agonist

Molecular Mechanism of Action of Non-peptide Ligands for Peptide Receptors

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor

Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor

Mutations in transmembrane segment VIJ of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists

Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT 1 Ligands: Susceptibility to Receptor Mutations

Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits

Mutations in transmembrane segment VIJ of the AT 1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists

Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis (CAPD) Solutions. A Biocompatibility Study Involving Human Polymorphonuclear Granulocytes Rather than Laboratory Animals

Molecular mechanism of activation and inhibition of 7TM peptide receptors

Extracellular and intracellular small-molecule galectin-3 inhibitors

A Selective Galactose–Coumarin-Derived Galectin‑3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis

Discovery and Optimization of the First Highly Effective and Orally Available Galectin‑3 Inhibitors for Treatment of Fibrotic Disease

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)

Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment

Suchergebnisse filtern